UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

62/m mit Dysphagie und Gewichtsverlust

Onkologie (Heidelberg, Germany), 2021-09, Vol.27, p.96-100

2021

Volltextzugriff (PDF)

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Journal of clinical oncology, 2004-01, Vol.22 (1), p.175-184

2004

Volltextzugriff (PDF)

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1501-1518

2001

Volltextzugriff (PDF)

Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie

Journal of clinical oncology, 2007-06, Vol.25 (18), p.2580-2585

2007

Volltextzugriff (PDF)

Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9250-9256

2005

Volltextzugriff (PDF)

62/m mit Dysphagie und Gewichtsverlust: Vorbereitung auf die Facharztprüfung: Fall 16

Der Onkologe, 2021-09, Vol.27 (Suppl 1), p.96-100

2021

Volltextzugriff (PDF)

The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan

Anti-cancer drugs, 2005-11, Vol.16 (10), p.1099-1108

2005

Volltextzugriff (PDF)

Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer

Journal of clinical oncology, 1999-03, Vol.17 (3), p.907-913

1999

Volltextzugriff (PDF)

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

Oncotarget, 2015-05, Vol.6 (14), p.12035-12047

2015

Volltextzugriff (PDF)

Molecular Mechanisms and Targeting of Colorectal Cancer

Seminars in oncology, 2005-12, Vol.32 (6), p.7-10

Vanhoefer, Udo

2005

Volltextzugriff (PDF)

Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus

United European gastroenterology journal, 2024-04, Vol.12 (3), p.399-411

2024

Volltextzugriff (PDF)

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas

Investigational new drugs, 2013-06, Vol.31 (3), p.642-652

2013

Volltextzugriff (PDF)

Epidermal growth factor receptor mutations may confer resistance or cross-resistance to cetuximab and panitumumab and can be detected in circulating tumor DNA

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.3549-3549

2015

Volltextzugriff (PDF)

Characterization of Protein Kinase chk1 Essential for the Cell Cycle Checkpoint after Exposure of Human Head and Neck Carcinoma A253 Cells to a Novel Topoisomerase I Inhibitor BNP1350

Molecular pharmacology, 2000-03, Vol.57 (3), p.453-459

2000

Volltextzugriff (PDF)

D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

Cancer research (Chicago, Ill.), 2001, Vol.61 (1), p.392-399

2001

Volltextzugriff (PDF)

Clinical predictive factors

European journal of cancer (1990), 2009-09, Vol.45, p.43-49

2009

Volltextzugriff (PDF)

New systemic frontline treatment for metastatic colorectal carcinoma

Cancer, 2004-04, Vol.100 (8), p.1558-1577

2004

Volltextzugriff (PDF)

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584

Seminars in oncology, 2003-06, Vol.30 (3 Suppl 6), p.32-38, Article as0093775403001234

2003

Volltextzugriff (PDF)

Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6809-6811

2005

Volltextzugriff (PDF)

Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e13100-e13100

2012

Volltextzugriff (PDF)

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

Annals of oncology, 2003-09, Vol.14 (9), p.1442-1448

2003

Volltextzugriff (PDF)

p53 and WAF1 Are Induced and Rb Protein Is Hypophosphorylated during Cell Growth Inhibition by the Thymidylate Synthase Inhibitor ZD1694 (Tomudex)

Molecular pharmacology, 1997-04, Vol.51 (4), p.630-636

1997

Volltextzugriff (PDF)

2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors

Cancer research (Chicago, Ill.), 2002-06, Vol.62 (11), p.3113-3119

2002

Volltextzugriff (PDF)

Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer

Journal of cancer research and clinical oncology, 2005-01, Vol.131 (1), p.67-72

2005

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(35)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Oncology
(26)
Biological And Medical Sciences
(18)
Medical Sciences
(18)
Female
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Chemotherapy
(13)
Pharmacology. Drug Treatments
(13)
Antineoplastic Agents
(12)
Male
(12)
Middle Aged
(12)
Adult
(11)
Aged
(11)
Colorectal Neoplasms - Drug Therapy
(9)
Tumors
(9)
Tumor Cells, Cultured
(8)
Treatment Outcome
(7)
Animals
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

62/m mit Dysphagie und Gewichtsverlust

Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview

Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group

62/m mit Dysphagie und Gewichtsverlust: Vorbereitung auf die Facharztprüfung: Fall 16

The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan

Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

Molecular Mechanisms and Targeting of Colorectal Cancer

Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas

Epidermal growth factor receptor mutations may confer resistance or cross-resistance to cetuximab and panitumumab and can be detected in circulating tumor DNA

Characterization of Protein Kinase chk1 Essential for the Cell Cycle Checkpoint after Exposure of Human Head and Neck Carcinoma A253 Cells to a Novel Topoisomerase I Inhibitor BNP1350

D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity

Clinical predictive factors

New systemic frontline treatment for metastatic colorectal carcinoma

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584

Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases

Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

p53 and WAF1 Are Induced and Rb Protein Is Hypophosphorylated during Cell Growth Inhibition by the Thymidylate Synthase Inhibitor ZD1694 (Tomudex)

2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors

Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer

Suchergebnisse filtern